← Back to Clinical Trials
Recruiting NCT04736732

NCT04736732 Institut de Recherche Cliniques de Montreal (IRCM) Post-COVID-19 (IPCO) Research Clinic

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04736732
Status Recruiting
Phase
Sponsor Emilia Falcone, MD
Condition Covid19
Study Type OBSERVATIONAL
Enrollment 650 participants
Start Date 2021-02-01
Primary Completion 2027-05-04

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 100 Years
Study Type OBSERVATIONAL
All Conditions
Interventions
Medical follow-up

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 650 participants in total. It began in 2021-02-01 with a primary completion date of 2027-05-04.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

While many COVID19 studies are focusing on the immediate biological impact of SARS-CoV2 infection, this multidisciplinary research clinic will inform the global community on its recovery phase across patient cohorts with different degrees of disease severity (asymptomatic, mild \[non-hospitalized\], moderate/severe \[hospitalized\]). The primary objectives are to: 1) evaluate the short- and long-term end-organ complications post-COVID-19 in relation to the severity of the acute COVID-19 infection and 2) establish a post-COVID-19 biobank. The secondary objective is to develop a model that can predict end-organ complications using epidemiological and clinical data. To complete the objectives, the study will follow 6 patient cohorts: Patients who had previous asymptomatic or mild COVID-19 (no need for oxygen), patients who had previous moderate/severe COVID-19 (patients who had an oxygen requirement; moderate=oxygen by nasal cannula; severe=oxygen by high flow nasal cannula, non-invasive positive pressure ventilation or intubation), patients who had COVID-19 but did not develop the post-COVID-19 condition, patients who have never had COVID-19, patients who had flu-like symptoms but did not have signs or symptoms related to the infection lasting beyond 4 weeks from the date of symptom-onset, and patients with flu-like symptoms and have signs or symptoms related to the infection lasting beyond 4 weeks from the date of symptom-onset. Patients will be recruited into these cohorts using a strategy that targets the following populations: patients that were hospitalized in centers across Montreal, patients already followed at the IRCM (non-COVID-19) clinic, essential workers, and members of the same household as patients already enrolled in the IPCO clinic research protocol. The IPCO clinic research protocol is the first in the province of Quebec to systematically follow patients post-COVID-19 for short- and long-term complications including end-organ damage while building an extensive biobank that can support future mechanistic research projects.

Eligibility Criteria

Inclusion Criteria: * Any gender, ≥ 18 years old * Current resident of Quebec * Speaks English or French * Have a personal email (to which to send reminders and questionnaire by email ) AND 1 of the following criteria: • Individuals with at least one COVID-19 positive PCR test, serology or antibody/antigen test in the last 60 months at day of recruitment. In the absence of a positive COVID-19 test, individuals with symptoms consistent with COVID-19 while living with a person who had a confirmed positive PCR, serology or antibody/antigen COVID-19 test in the last 60 months at day of recruitment (epidemiologic link). OR • Individuals who tested negative for COVID-19 while living with a household member who tested positive for COVID-19 or had a close contact with the viral infection in the context of their work, and never had any COVID-19 related symptoms (presumed COVID negative control group). OR • Individuals who don't have any COVID-19 related symptoms actually, have never had tested positive, and have had at least one negative PCR, serology or antibody/antigen COVID-19 test (presumed COVID negative control group). OR • Individuals with an undiagnosed viral infection in the last 60 months at day of recruitment and have persistent symptoms (or not) after the participant has recovered from a viral infection. Exclusion Criteria: * Any participant not deemed appropriate for enrollment according to the PI * Known pregnancy (female will not be automatically screened for pregnancy upon enrollment unless there is a possibility that they might be pregnant)

Contact & Investigator

Central Contact

Emilia Liana Falcone, M.D., Ph.D.

✉ Emilia.falcone@ircm.qc.ca

📞 514-987-5610

Principal Investigator

Emilia Liana Falcone, M.D., Ph.D.

PRINCIPAL INVESTIGATOR

IRCM

Frequently Asked Questions

Who can join the NCT04736732 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Covid19. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04736732 currently recruiting?

Yes, NCT04736732 is actively recruiting participants. Contact the research team at Emilia.falcone@ircm.qc.ca for enrollment information.

Where is the NCT04736732 trial being conducted?

This trial is being conducted at Montreal, Canada.

Who is sponsoring the NCT04736732 clinical trial?

NCT04736732 is sponsored by Emilia Falcone, MD. The principal investigator is Emilia Liana Falcone, M.D., Ph.D. at IRCM. The trial plans to enroll 650 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology